



Synta Announces Presentations at the 2014 American Society for Clinical Oncology (ASCO) Annual Meeting

May 28, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)--May 28, 2014-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced scheduled presentations at the 2014 American Society for Clinical Oncology (ASCO) Annual Meeting, which is taking place May 30 – June 3 in Chicago.

GALAXY-2 trial design

"GALAXY-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma"

Abstract #: TPS8118^

Date and time: May 31, 1:15 – 5:00 PM

Location: General Poster Session – Lung Cancer – Non-small Cell Metastatic. S Hall A2

Presenter: Suresh S. Ramalingam, MD, Winship Cancer Institute of Emory University, Atlanta, GA

Trial design for investigator-sponsored trial of ganetespib in sarcoma

"SARC023: Phase I/II trial of ganetespib in combination with sirolimus for refractory sarcomas and malignant peripheral nerve sheath tumors (MPNST)"

Abstract #: TPS10603

Date and time: June 2, 8:00 – 11:45 AM

Location: General Poster Session – Sarcoma. S Hall A2

Presenter: AeRang Kim, MD, PhD, Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC

Ganetespib in pediatric sarcomas (preclinical)

"Heat-shock protein 90 inhibition in pediatric sarcomas"

Abstract #: 10057

Date and time: June 2, 8:00 – 11:45 AM.

Location: General Poster Session – Pediatric Oncology. S Hall A2

Presenter: Fernanda Irene Arnaldez, MD, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD

About Ganetespib

Ganetespib, an investigational drug candidate, is a selective inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone which controls the folding and activation of a number of client proteins that drive tumor development and progression. Many solid and hematologic tumors are dependent on Hsp90 client proteins including proteins involved in "oncogene addiction" (ALK, HER2, mutant BRAF and EGFR, androgen receptor, estrogen receptor, and JAK2); proteins involved in resistance to chemotherapy and radiation therapy (ATR, BCL2, BRCA1/2, CDK1/4, CHK1, survivin, and WEE1); proteins involved in angiogenesis (HIF-1 α , VEGFR, PDGFR, and VEGF); and proteins involved in metastasis (MET, RAF, AKT, MMPs, HIF-1 α , and IGF-1R). In preclinical models, inhibition of Hsp90 by ganetespib results in the inactivation, destabilization, and eventual degradation of these cancer-promoting proteins. Ganetespib is being evaluated in trials in lung cancer, breast cancer, and other tumor types. The most common adverse event seen to date has been transient, mild or moderate diarrhea, which has been manageable with standard supportive care. Information on these trials can be found at www.clinicaltrials.gov. Ganetespib has received Fast Track designation from FDA for second-line treatment of non-small cell lung adenocarcinoma in combination with docetaxel.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were invented by Synta scientists using its compound library and discovery capabilities. For more information, please visit www.syntapharma.com.

Source: Synta Pharmaceuticals Corp.

Synta Pharmaceuticals Corp.

Steven Bernitz, 781-541-7250

Senior Vice President, Corporate Development

sbernitz@syntapharma.com

or

Argot Partners
Andrea Rabney, 212-600-1494
andrea@argotpartners.com
or
Argot Partners
Eliza Schleifstein, 917-763-8106
eliza@argotpartners.com